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HIV-1 protease inhibitor (PI), nelfinavir (NFV) induced growth arrest and apoptosis of NCI-H460 and -H520, A549, EBC-1 and ABC-
1 non-small-cell lung cancer (NSCLC) cells in association with upregulation of p21
waf1, p27
kip1 and p53, and downregulation of Bcl-2
and matrix metalloproteinase (MMP)-2 proteins. We found that NFV blocked Akt signalling in these cells as measured by Akt kinase
assay with glycogen synthase kinase-3a/b (GSK-3a/b) as a substrate. To explore the role of Akt signalling in NFV-mediated growth
inhibition of NSCLC cells, we blocked this signal pathway by transfection of Akt small interfering RNA (siRNA) in these cells; transient
transfection of Akt siRNA in NCI-H460 cells decreased the level of Bcl-2 protein and slowed their proliferation compared to the
nonspecific siRNA-transfected cells. Conversely, forced-expression of Akt partially reversed NFV-mediated growth inhibition of these
cells, suggesting that Akt may be a molecular target of NFV in NSCLC cells. Also, we found that inhibition of Akt signalling by NFV
enhanced the ability of docetaxel to inhibit the growth of NCI-H460 and -H520 cells, as measured by MTT assay. Importantly, NFV
slowed the proliferation and induced apoptosis of NCI-H460 cells present as tumour xenografts in nude mice without adverse
systemic effects. Taken together, this family of compounds might be useful for the treatment of individuals with NSCLC.
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Lung cancer is the leading cause of cancer death all over the world.
Non-small-cell lung cancer (NSCLC) comprises adeno-, squamous
and large cell carcinoma, and constitutes the majority of lung
cancers. Despite the development of new treatment strategies using
novel anticancer drugs, the 5-year survival rates have not
improved dramatically (Nemunatis et al, 2000; Khuri et al,
2001). Therefore, novel approaches to the treatment of this disease
are urgently needed.
The uncontrolled proliferation of cancer cells is often associated
with alteration of growth factor receptors such as the epidermal
growth factor receptor family in lung cancer. This is often
accompanied with the activation of various intracellular signal
pathways causing enhanced cellular proliferation and/or decreased
apoptosis. Phosphatidylinositol 3-kinase (PI3K), which relays
various signal pathways via the production of phosphatidylinosi-
tide lipids, has been identified as one of the core intracellular
signalling molecules in the stimulation of growth factors,
subsequently phosphorylating and activating a serine/threonine
kinase, Akt/protein kinase B (PKB) (Ullich and Schlessinger, 1990;
Franke et al, 1997; Toker and Cantley, 1997; Cantley and Neel,
1999). Akt phosphorylates several antiapoptotic proteins, includ-
ing the Bcl-2 family member BAD (Datta et al, 1997), caspase-9
(Fujita et al, 1999; Di Cristofano and Pandolfi, 2000), the inhibitor
of nuclear factor-kB (NF-kB), kinase IKKa (Di Cristofano and
Pandolfi, 2000) and glycogen synthase kinase 3 (GSK-3) (Cross
et al, 1995; Pap and Cooper, 1998), resulting in prolonged cell
survival. Glycogen synthase kinase 3 was initially discovered as an
enzyme that inactivates glycogen synthesis in response to insulin
stimulation (Welsh and Proud, 1993). Recently, GSK-3 is
considered to be involved in multiple cellular processes, such as
metabolism (Cross et al, 1995), tumorigenesis (Rubinfeld et al,
1996), differentiation (Harwood et al, 1995; He et al, 1995) and
apoptosis (Pap and Cooper, 1998). Activated GSK-3 suppresses cell
proliferation and survival (Brunet et al, 1999; Kane et al, 1999).
Several signal pathways, including Akt, control GSK-3 activity
(Sutherland et al, 1993; Cohen and Frame, 2001). Akt phosphory-
lates GSK-3a/b on Ser
21 and Ser
9 to inactivate its kinase activity
(Sutherland et al, 1993; Cross et al, 1995). Previous studies showed
that the PI3K/Akt pathway is activated in a variety of cancers,
including those from prostate, ovary, breast, pancreas and lung
(Cheng et al, 1992; Izuishi et al, 2000; Brognard et al, 2001; Kulik
et al, 2001). Thus, the PI3K/Akt/GSK-3 signal pathway might be a
promising molecular target of cancer treatment.
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inhibitors (PIs) have become important tools in the treatment of
HIV infection; these include saquinavir mesylate (SAQ), ritonavir
(RTV), nelfinavir mesylate (NFV) and indinavir sulphate (IDV).
Recent studies showed that PIs possess antitumour activity, which
is independent of their ability to inhibit HIV protease: we found
that PIs induced growth arrest and differentiation of NB4 and
HL-60 human myeloid leukemia cells, and enhanced the ability of
all-trans retinoic acid (ATRA) to decrease proliferation and
increase differentiation of these cells (Ikezoe et al, 2000). In
addition, PIs induced growth arrest and apoptosis of multiple
myeloma (MM) cells via inhibition of signalling through activated
signal transducer and activator of transcription 3 (STAT 3) and
extracellular signal-related kinase1/2 (ERK1/2) (Ikezoe et al,
2004b). More recently, we have shown that RTV blocked
docetaxel-induced expression of cytochrome P450 3A4 (CYP3A4)
and enhanced antitumour effects of docetaxel against DU145
human prostate cancer cells in vitro and in vivo (Ikezoe et al,
2004a). Moreover, other investigators showed that PIs can decrease
proliferation of Kaposi sarcoma as well as prostate cancer cells via
inhibition of NF-kB activity (Pajonk et al, 2002; Pati et al, 2002;
Sgadari et al, 2002).
In this study, we found that NFV blocked Akt signalling and
induced growth arrest and apoptosis of human NCI-H460 and
-H520 NSCLC cells in vitro and in vivo.
MATERIALS AND METHODS
Cell lines and cell culture
NCI-H520 (squamous cell carcinoma) and -H460 (large cell), A549
(adenocarcinoma), ABC-1 (adenocarcinoma) and EBC-1 (squa-
mous cell carcinoma) human NSCLC cells were maintained in
RPMI 1640 with 10% FCS.
Chemicals
Saquinavir mesylate (Roche, Branchburg, NJ, USA), RTV (Abbott
Labs, North Chicago, IL, USA) and NFV (Japan Tobacco
Specification, Tokyo, Japan) were dissolved in 50% dimethyl
sulphoxide (DMSO; Burdick & Jackson, Muskegon, MI, USA) to
a stock concentration of 10
 2 M and stored at  801C. Docetaxel
(Aventis Pharmaceuticals Inc., Tokyo, Japan) was dissolved in PBS
to a stock concentration of 10
 4 M and stored at 41C. The PI3-
kinase inhibitor LY294002 (Calbiochem, San Diego, CA, USA) was
dissolved in DMSO at a stock concentration of 2 10
 2 M and was
used at 10–60mM. Insulin-like growth factor 1 (IGF-1) (Austral
Biologicals, San Ramon, CA, USA) was stored at  201C and was
used at final concentration of 50nM.
MTT assay
NCI-H460 and -H520 cells (10
5ml
 1) were incubated with various
concentrations of either PIs (10–50mM) or LY294002 (10–60mM)
for 3 days in 96-well plates (Flow Laboratories, Irvine, CA, USA).
After culture, cell number and viability were evaluated by
measuring the mitochondrial-dependent conversion of the tetra-
zolium salt, MTT (Sigma, St. Louis, MO, USA), to a coloured
formazan product as previously described.
Cell cycle analysis by flow cytometry
Cell cycle analysis was performed on NSCLC cells incubated for 48h
with NFV (20 or 30mM). The cells were fixed in chilled methanol
overnight before staining with 50mgml
 1 propidium iodide in the
presence of 1mgml
 1 RNase (100Uml
 1; Sigma) and 0.1% NP40
(Sigma). Analysis was performed immediately after staining using a
FACScan (Becton Dickinson, Mountain View, CA, USA).
Assessment of apoptosis
Apoptotic cell death was examined by terminal deoxyribonucleo-
tide transferase-mediated dUTP nick-end labelling (TUNEL)
method. The TUNEL assay was performed using the In Situ Cell
Death Detection kit (Roche Molecular Biochemicals, Mannheim,
Germany), as previously described (Yang et al, 2004).
Plasmid and transfection
NCI-H460 cells were transiently transfected with Gag-AKT
expression vector (Burgering and Coffer, 1995) using the
GenePORTER transfection reagent (Gene Therapy Systems, Inc.,
San Diego, CA, USA).
Western blot analysis
NCI-H460 and -H520 cells (3 10
5ml
 1) were plated in 60mm
plates and cultured with NFV (20–40mM, 24h) or IGF-1
(50ngml
 1, 30min) either alone or in combination. After
incubation, cells were washed twice in PBS, and whole-cell lysates
were prepared as previously described (Yang et al, 2004). Proteins
were resolved on a 4–15% SDS polyacrylamide gel, transferred to
an immobilon polyvinylidene difluoride membrane (Amersham
Corp., Arlington Heights, IL, USA), and probed sequentially with
antibodies. Anti-p-Akt (Ser473) (Cell Signaling Technology,
Beverly, MA, USA), -Akt (Cell Signaling Technology), p-ERK1/2
(Tyr202/Tyr204) (Cell Signaling Technology), ERK2 (sc-154, Santa
Cruz, CA, USA), -p53 (Calbiochem, Darmstadt, Germany), -Bcl-2
(sc-7382, Santa Cruz), -Bcl-xL (Cell Signaling Technology), -matrix
metalloproteinase (MMP)-2 (SC-10736), -p27
kip1 (sc-527, Santa
Cruz), -p21
waf1 (Abcam Ltd, Cambridge, UK) and (-actin
antibodies (sc-1615, Santa Cruz) were used. The blots were
developed using the enhanced chemiluminescence kit (Amersham
Corp.).
Akt immunoprecipitation kinase assay
Serum-starved NCI-H460 cells (24h) were cultured either with
or without NFV (20mM). After 24h, cells were exposed to IGF-1
(50ngml
 1) for 30min. Cells were harvested and cell lysates were
prepared. Akt kinase assay was performed using Akt kinase assay
kit (Cell Signaling Technology), according to the manufacturer’s
instructions. Briefly, 200mg of cell lysates were incubated for 12h
with protein G-agarose beads bearing anti-Akt on a rotator at
41C to immunoprecipitate Akt. This precipitate was next used to
phosphorylate a specific substrate, the recombinant GSK-3a/b
protein expressed in Escherichia coli. Briefly, 1mg of recombinant
GSK-3a/b was incubated with Akt-antibody–protein G–agarose
complexes in the presence of magnesium/ATP mixture for 30min
at 371C. Samples were boiled for 5min, resolved on 10% SDS–
PAGE, and transferred onto immobilon polyvinylidene difluoride
membrane. The membranes were incubated sequentially with anti-
p-GSK-3a/b (Ser
21/9) and -Akt antibodies and the blots were
developed using the enhanced chemiluminescence kit (Amersham
Corp).
Small interfering RNA (siRNA) transfection
Signalsilence Akt siRNA kit (Cell Signaling Technology) was
utilised to downregulate Akt protein in NCI-H460 cells. In brief,
NCI-H460 cells were transfected with siRNA (final concentration
of 100nM) using transfection reagent (Cell Signaling Technology).
After 2 days, cells were harvested and subjected to Western blot
analysis. The membrane was probed sequentially with anti-p-Akt,
-Akt, -Bcl-2, -Bcl-xL and -b-actin antibodies. Control cells were
transfected with nonspecific siRNA and cultured under the
identical condition.
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Either nonspecific or Akt siRNA transiently transfected NCI-H460
cells were plated in 96-well plates (Flow Laboratories) and cultured
for various durations as indicated. Cell number and viability were
evaluated by Trypan blue exclusion test.
Mice
A total of 10 male triple-deficient BALB/c nude mice at 6 weeks
of age were purchased from JAPAN SLC. Inc. (Shizuoka, Japan),
and were maintained in pathogen-free conditions with irradiated
chow. Animals were bilaterally, subcutaneously (s.c.) injected with
2 10
6 NCI-H460 cells/tumour in 0.1ml Matrigel (Collaborative
Biomedical Products, Bedford, MA, USA). Mice were divided
randomly into two groups of five mice each. Either NFV
(60mgkg
 1mouse
 1) or control diluent was administered orally
five times a week. The treatment was begun 1 day after NCI-H460
cells were injected into mice and continued until mice were killed.
The dose of NFV was determined by our preliminary studies (data
not shown). Tumours were measured every week with vernier
calipers. Tumour sizes were calculated by the formula: a b c,
where ‘a’ is the length and ‘b’ is the width and ‘c’ is the height in
millimeters. At the end of the experiment, animals were killed by
CO2 asphyxiation and tumour weights were measured after their
careful resection. Tumour tissue was collected for analysis. The
experiments, approved by the Review Board of Kochi University,
were performed in strict accordance with the UKCCCR guidelines
(Workman et al, 1998).
Terminal deoxyribonucleotide transferase-mediated dUTP
nick-end labelling assay for tumour xenografts
Tumours were fixed for 12h in 10% neutral-buffered formaldehyde
after killing, tissue blocks were embedded in paraffin and stained
with In Situ Cell Death Detection kit (Roche Molecular Biochem-
icals), and examined by microscope.
Data analysis
Combination index (CI) of NFV and docetaxel in NSCLC
cells was calculated using the median effect method of Chou and
Talalay (1984) (Calcusyn Software available from Biosoft,
Cambridge, United Kingdom). Combination index values less
than 1 indicate synergy, a CI¼1 indicates an additive effect
and a CI more than 1 indicates antagonism between the two
agents. The difference between two groups under multiple
conditions was assessed by one-way analysis of variance (ANOVA)
followed by Boneferroni’s multiple comparison tests using
PRISM statistical analysis software (GraphPad Software, San
Diego, CA, USA). The non-parametric Mann–Whitney U-test
was performed to assess the difference between two groups in the
in vivo studies.
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Figure 1 Effect of PIs on the proliferation and apoptosis of human NSCLC cells. Panels (A–E) MTT assay. NCI-H460 (A), NCI-H520 (B), A549 (C),
ABC-1 (D), EBC-1 (E) cells (10
5ml
 1) were plated in 96-well plates and cultured either with or without PIs (10–50mM). After 3 days, the cells were treated
with MTT for 4h at 371C, and MTT activity was measured. Results represent the mean7s.d. of three experiments performed in triplicate.
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Effect of PIs on the proliferation and apoptosis of human
NSCLC cells
The effect of PIs on proliferation of NSCLC cells was examined by
MTT assay. Ritonavir, SAQ and NFV effectively inhibited the
proliferation of both NCI-H460 (Figure 1A) and -H520 (Figure 1B)
cells with an effective doses that inhibited 50% cell proliferation
(ED50s) of approximately 40, 25 and 10mM, respectively, on the
third day of culture. Similarly, the proliferation of A549
(Figure 1C), ABC-1 (Figure 1D) and EBC-1 (Figure 1E) was
inhibited by PIs. Because NFV had the strongest antigrowth
activity of the PIs, it was used in further analysis. We explored the
effects of NFV on cell cycle distribution of NSCLC cells. NFV (20 or
30mM, 48h) significantly increased the percentage of cells in the
G0/G1 phase (Table 1). Concomitant with these changes, the
percentage of cells in S phase significantly decreased (Table 1).
Terminal deoxyribonucleotide transferase-mediated dUTP nick-
end labelling assay was utilised to examine the proapoptotic effect
of NFV. Nelfinavir induced apoptosis of these cells in a dose- and
time-dependent manner (Table 2); NFV (20 or 40mM) induced a
mean 19.374.4% (7s.d.) and 24.974.4% of the NCI-H460 cells
to become apoptotic at 24h. The TUNEL-positive population
increased to a mean of 33.372.9 and 50.478.6% (Po0.005) at
48h, respectively (Table 2). Similarly, NFV induced apoptosis of
A549 cells in a dose- and time-dependent manner (Table 2).
Nelfinavir modulates the levels of Bcl-2, p53, p21
waf1,
p27
kip1 and MMP-2 in NSCLC cells
The effect of NFV on the expression of the antiapoptotic Bcl-2
family members was examined in NSCLC cells by Western blot
analysis (Figure 2). Both NCI-H460 and -H520 cells expressed
Bcl-2 and Bcl-xL proteins at a high level (Figure 2). Exposure of
either NCI-H460 or -H520 cells to NFV (20mM, 24h) decreased
levels of Bcl-2 by either 70 or 80%, respectively (Figure 2). On the
other hand, the levels of Bcl-xL were not modulated in these cells
under the identical culture conditions (Figure 2).
We further explored whether NFV modulated the levels of the
cell cycle checkpoint proteins, p53, p21
waf1 and p27
kip1 in NSCLC
cells (Figure 2). NCI-H460 and -H520 cells possess the wild-type
and mutant type of p53 gene, respectively (Mitsudomi et al, 1992);
exposure of these cells to NFV (20mM, 24h) increased their levels
of p53 by 20- and 10-fold, respectively, compared with control cells
(Figure 2). Expression of p21
waf1 was negligible in both cell lines;
however, exposure of these cells to NFV dramatically induced
expression of p21
waf1 protein (Figure 2), suggesting that induction
of p21
waf1 mediated by NFV was p53-independent. Likewise, levels
of p27
kip1 were also markedly induced by NFV in NCI-H460
(30-fold) and -H520 (50-fold) cells compared with control cells
(Figure 2).
The matrix metalloproteinases (MMPs) including MMP-2
degrade basement membranes and stromal extracellular matrix,
resulting in tumour invasion and metastasis (Choi et al, 2005).
NCI-H460 cells expressed MMP-2, and NFV downregulated this
protein by 90% (Figure 2). NCI-H520 cells also expressed MMP-2,
although the level was much lower than that in NCI-H460 cells.
NFV slightly downregulated MMP-2 protein in these cells
(Figure 2).
Effect of NFV on Akt signalling in NSCLC cells
Both NCI-H460 and -H520 cells constitutively expressed the
phosphorylated form of Akt (Figure 3A). Exposure of these cells
Table 1 Effect of NFV on cell cycle distribution in NSCLC cells (%)
NFV (lM) NCI-H460 NCI-H520 A549 EBC-1
— 56.9871.21 61.1674.70 69.1271.58 53.1674.19
G0/G1 20 63.2273.00 65.1970.22 75.1374.36 58.2073.00
30 76.5972.71** 78.3373.07** 94.5570.78** 83.3571.63**
— 19.8471.08 9.3971.51 14.4571.48 18.8972.43
G2/M 20 11.5773.52 8.3371.07 10.9071.27 13.7175.13
30 11.1574.59* 8.4670.62 3.4570.49** 7.0070.14*
— 21.7171.12 31.1475.76 17.2971.72 27.7973.02
S 20 22.7673.08 29.2371.92 15.8970.69 23.0773.53
30 10.9071.13** 13.1173.27** 1.8470.37** 8.0570.39**
Cells were exposed to NFV (20 or 30mM). After 48h, cell cycle distribution was
analysed by FACscan. Significance of difference between control cells and cells
cultured with NFV was calculated by paired t-test. Results represent the mean7s.d.
of three experiments performed in triplicate. *Po0.05; **Po0.005. NFV¼nelfinavir.
Table 2 Proapoptotic effect of NFV on NSCLC cells (TUNEL-positive
cells, %)
Day 1 Day 2
NFV(mM) — 20 40 — 20 40
NCI-H460 1.070.3 19.374.4* 24.974.4* 2.470.3 33.372.9* 50.478.6*
A549 4.671.9 24.275.2* 36.672.1* 7.472.1 36.274.0* 59.177.2*
Cells were exposed to NFV (20 or 40mM). Apoptotic cells were measured by TUNEL
assay on day 1 or day 2 of culture. Significance of difference between control cells and
cells cultured with NFV was calculated by paired t-test. Results represent the
mean7s.d. of two experiments performed in triplicate. *Po0.01. NFV¼nelfinavir;
TUNEL¼terminal deoxyribonucleotide transferase-mediated dUTP nick-end labelling.
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Figure 2 Nelfinavir modulates the levels of Bcl-2, p53, p21
waf1, p27
kip1
and MMP-2 in NSCLC cells. Western blot analysis. NCI-H460 and -H520
cells were cultured with either NFV (20mM) or control diluent. After 24h,
cells were harvested and subjected to Western blot analysis. The
polyvinylidene difluoride membrane was sequentially probed with anti-
p21
waf1,-p27
kip1, -p53, -Bcl-2, -Bcl-xL, -MMP-2 and -b-actin antibodies, and
band intensities were measured by densitometry and normalised for
b-actin. NFV, nelfinavir; RTV, ritonavir; SQV, saquinavir.
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sto NFV (20mM, 24h) decreased levels of p-Akt (Ser473) protein by
80 and 60%, respectively (Figure 3A). On the other hand, NFV
(20mM, 24h) was not able to downregulate levels of p-ERK1/2
(Tyr202/Tyr204) in these cells (Figure 3A). We further explored
whether NFV downregulated IGF-1-stimulated expression of Akt
in these cells. Exposure of NCI-H460 cells to IGF-1 (50ngml
 1,
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C
Figure 3 Effect of NFV on Akt signalling in NCI-H460 cells. Panels (A, B), Western blot analysis. (A) NCI-H460 and -H520 cells were cultured with
either NFV (20mM) or control diluent. After 24h, cells were harvested and subjected to Western blot analysis. The polyvinylidene difluoride membrane was
sequentially probed with anti-p-Akt (Ser473), -Akt, p-ERK1/2 (Tyr202/Tyr204), -ERK1/2, and -b-actin antibodies, and band intensities were measured by
densitometry. (B) NCI-H460 cells were cultured with either NFV (20mM) or control diluent. After 24h, cells were exposed to IGF-1 (50ngml
 1) for
30min, harvested, subjected to Western blot analysis, and polyvinylidene difluoride membrane was sequentially probed with anti-p-Akt, -Akt, and -b-actin
antibodies. Band intensities were measured by densitometry. (C) Akt kinase assay. NCI-H460 cells were cultured with either NFV (20mM) or control diluent.
After 24h, cells were exposed to IGF-1 (50ngml
 1) for 30min. Cells were harvested, proteins were prepared and subjected to Akt kinase assay with GSK-3
as a substrate. Membrane was sequentially probed with antibodies against -p-GSK3a/b (Ser
21/9) and –Akt. Band intensities were measured by densitometry.
NFV, nelfinavir.
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Figure 4 Effect of PI3 kinase inhibitor LY294002 on the growth of NSCLC cells. (A) MTT assay. NCI-H460 and NCI-H520 cells (10
5ml
 1) were plated in
96-well plates and cultured either with or without LY294002 (10–60mM). After 3 days, the cells were cultured with MTT for 4h at 371C, and MTT activity
was measured. Results represent the mean7s.d. of three experiments performed in triplicate. (B) Terminal deoxyribonucleotide transferase-mediated
dUTP nick-end labelling assay. NCI-H460 cells were plated in 24-well plates and cultured either with or without LY294002 (10 or 20mM); after 48h,
apoptosis was measured by TUNEL assay. Results represent the mean7s.d. of two experiments performed in triplicate. (C) Western blot analysis. NCI-
H460 and -H520 cells were cultured with either LY294002 (20mM) or control diluent. After 24h, cells were harvested, and subjected to Western blot
analysis. The polyvinylidene difluoride membrane was sequentially probed with anti-p-Akt, -Akt and -b-actin antibodies. LY, LY294002. (D) LY294002
enhanced the ability of NFV in NCI-H460 cells. MTT assay. NCI-H460 cells (10
5ml
 1) were plated in 96-well plates and cultured with NFV (10mM)o r
LY294002 (10mM) either alone or in combination. After 2 days, their viability was measured by MTT assay. The statistical significance was determined by
ANOVA followed by Boneferroni’s multiple comparison tests. Results represent the mean7s.d. of three experiments performed in triplicate.
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s30min) increased levels of the phosphorylated form of Akt by 30-
fold. Preincubation of these cells with NFV (20mM, 24h) decreased
IGF-1-induced levels of the phosphorylated form of Akt by 80%.
On the other hand, NFV did not affect levels of total Akt
(Figure 3B). Furthermore, the effect of NFV on Akt signalling was
investigated by the Akt kinase assay with GSK3a/b as a substrate
(Figure 3C). NCI-H460 cells, which were serum-starved for 24h,
possessed measurable Akt activity (Figure 3C, lane 1). Similarly
treated cells exposed to IGF-1 (50ngml
 1, 30min) increased the
level of the phosphorylated form of the Akt substrate (GSK3a/b)b y
three-fold. Preincubation of these cells with NFV (20mM,2 4 h )
inhibited the IGF-1-stimulated Akt kinase activity by 73%
(Figure 3C).
Inhibition of Akt signalling by LY294002 enhanced the
ability of NFV in NSCLC cells
To study the role of Akt signalling in survival of NSCLC cells, we
blocked this pathway using a PI3 kinase inhibitor LY294002
(Vlahos et al, 1994). As shown in Figure 4A, LY294002 (20–60mM,
3 days) effectively inhibited the proliferation of both NCI-H460
and -H520 cells with an ED50s of approximately 20mM. LY294002
(10 or 20mM, 48h) induced apoptosis of NCI-H460 cells in a dose-
dependent manner (Figure 4B). LY294002 (20mM, 24h) completely
blocked phosphorylation of Akt in these cells (Figure 4C).
Furthermore, we explored the impact of blockade of Akt signalling
by LY294002 on the effect of NFV in NSCLC cells; LY294002
significantly enhanced the ability of NFV to inhibit the growth of
NCI-H460 cells (Figure 4D).
Transfection of Akt siRNA in NCI-H460 cells
In order to block Akt signalling in NSCLC cells, double-stranded
Akt siRNA molecules were delivered into the NCI-H460 cells.
Transient transfection of these cells with Akt siRNA almost
completely blocked expression of Akt protein (Figure 5A).
Interestingly, the level of Bcl-2 protein decreased by about 80%
in Akt siRNA-transfected cells, compared with nonspecific siRNA-
transfected cells. In contrast, the levels of Bcl-xL, p53 and p27
kip1
were not modulated after transfection of Akt siRNA (Figure 5A).
The control and Akt siRNA transiently transfected NCI-H460 cells
were incubated for 3 days in 96-well plates. The cell numbers and
viability were evaluated by Trypan blue exclusion test on each day.
The cell growth of Akt siRNA-transfected NCI-H460 cells was
significantly slowed compared with the nonspecific siRNA-
transfected control cells (Po0.001) (Figure 5B). Furthermore, we
assessed whether downregulation of Akt by siRNA induced
apoptosis of NCI-H460 cells. As shown in Figure 5C, 2475% of
Akt siRNA-transfected cells become apoptotic on the second day
of culture (Figure 5C). On the other hand, merely 7% of control
cells became apoptotic (Figure 5C).
Forced-expression of Akt partially reversed NFV-mediated
growth inhibition of NCI-H460 cells
NCI-H460 cells were transiently transfected with Akt expression
vector or an empty vector. After 48h of transfection, the levels of
the phosphorylated and total Akt proteins were measured by
Western blot analysis (Figure 6A). Also, cells were re-plated in
96-well plate and exposed to either NFV or control diluent for 48h.
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Figure 5 Transfection of Akt siRNA decreased levels of Akt and Bcl-2 and slowed the proliferation of NCI-H460 cells. (A) Transfection of Akt siRNA.
NCI-H460 cells were transfected with either Akt siRNA or nonspecific siRNA. After 2 days, cells were harvested, proteins were extracted and subjectedt o
Western blot analysis. Membrane was probed sequentially with antibodies against Akt, -Bcl-2, -Bcl-xL, -p53, p27
kip1 and b-actin. Blots were developed using
the enhanced chemiluminescence kit. (B) Trypan blue exclusion test. After 2 days from transfection, the control and Akt siRNA transiently transfected NCI-
H460 cells were harvested, re-plated in 96-well plates, and incubated for 3 days. Cell numbers and viability were evaluated at the indicated time pointb y
Trypan blue exclusion test. Results represent the mean7s.d. of three experiments performed in triplicate. (C) Terminal deoxyribonucleotide transferase-
mediated dUTP nick-end labelling assay. NCI-H460 cells were transfected with either Akt siRNA or nonspecific siRNA. After 2 days, apoptosis was
measured by TUNEL assay. Results represent the mean7s.d. of two experiments performed in triplicate. siRNA, small interfering RNA.
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sCell viability was measured by MTT assay (Figure 6B). Akt and
empty vector transfected NCI-H460 cells possessed almost
identical MTT activity (Figure 6B); however, when these cells
were exposed to NFV (10 or 20mM, 48h), MTT activity in Akt-
transfected NCI-H460 cells was significantly higher than that in
empty vector-transfected cells (Figure 6B). For example, NFV
(10mM, 48h) decreased MTT activity in empty vector-transfected
cells by 4772% compared to control cells. On the other hand,
MTT activity in Akt-overexpressing cells cultured with 10mM NFV
was inhibited by 3974% (Po0.05). Next, TUNEL assay was
utilised to examine the proapoptotic effect of NFV on Akt and
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Figure 6 Forced-expression of Akt prevented NFV-mediated growth
inhibition of NCI-H460 cells. (A) NCI-H460 cells were transiently
transfected with either Akt or empty vector. After 48h, cells were
harvested and subjected to Western blot analysis to measure the level of
p-Akt and total Akt. (B) At the same time, cells were exposed to either
NFV (10 or 20mM) or control diluent for 48h. At the end of the
experiment, cell viability was measured by MTT assay. Results represent the
mean7s.d. of triplicate wells. (C) At the same time, cells were plated in 24-
well plates and cultured either with or without NFV (20mM and 40mM);
after 48h, apoptosis was measured by TUNEL assay. Results represent the
mean7s.d. of two experiments performed in triplicate. NFV, nelfinavir.
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Figure 7 Nelfinavir (NFV) enhances antiproliferative effects of docetaxel
in NSCLC cells. (A) NCI-H460 and -H520 cells (10
5ml
 1)w e r ep l a t e di n
96-well plates and cultured either with or without NFV (10mM). After 3h,
cells were exposed to docetaxel (1nM) for 2 days, and their cells viability was
measured by MTT assay. Results represent the mean7s.d. of three
experiments performed in triplicate. (B) NCI-H460 and -520 cells (10
5ml
 1)
were plated in 96-well plates and cultured either with or without LY294002
(10mM). After 3h, cells were exposed to docetaxel (1nM)f o r2d a y sa n d
their viability was measured by MTT assay. The statistical significance was
determined by ANOVA followed by Boneferroni’s multiple comparison
tests. Results represent the mean7s.d. of three experiments performed in
triplicate. (C) NCI-H460 cells were cultured with NFV, docetaxel or both
agents at various concentrations. Combination index (CI) was determined
using the median effect method. A CI values less than 1 indicate synergy,
CI¼1 indicates an additive effect and a CI more than 1 indicates antagonism
between the two agents. Doc, docetaxel; LY, LY294002.
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sempty vector-transfected NCI-H460 cells (Figure 6C). When these
cells were exposed to NFV (20 or 40mM, 48h), TUNEL-positive
cells in empty vector-transfected NCI-H460 cells were significantly
higher than that in Akt-transfected cells (Figure 6C). For example,
NFV (20mM, 48h) induced a mean 33.372.9% (7s.d.) of empty
vector-transfected NCI-H460 cells to become apoptotic; on the
other hand, only a mean 20.671.9% (7s.d.) of Akt-overexpressing
cells become apoptotic (Po0.05). These results suggested that
forced-expression of Akt partially reversed NFV-mediated growth
inhibition of NCI-H460 cells.
Inhibition of Akt signalling by NFV or LY294002 sensitised
NSCLC cells to antiproliferative effect of docetaxel
We explored whether inhibition of Akt signalling by either NFV or
LY294002 sensitised NSCLC cells to docetaxel-mediated growth
inhibition. The NCI-H460 and -H520 cells were preincubated with
NFV (10mM) for 3h and exposed to docetaxel (1nM). After 48h,
cell number was assessed by MTT assay (Figure 7A, left panel).
Either NFV (10mM) or docetaxel (1nM) alone inhibited the growth
of NCI-H460 cells by 39 or 21%, respectively. The combination of
NFV and docetaxel inhibited the growth of these cells by 51%
compared to control cells (Figure 7A). Statistical analysis with
ANOVA showed significant difference between either drug alone
and combination of both (Po0.001). Similarly, NFV enhanced
antiproliferative activity of docetaxel against NCI-H520 cells
(Figure 7A, right panel). We next studied the interaction of
LY294002 (PI3K inhibitor) and docetaxel (Figure 7B). Cells were
preincubated with LY294002 (10mM) for 3h and exposed to
docetaxel (1nM, 48h). Either LY294002 (10mM) or docetaxel (1nM)
alone inhibited the growth of NCI-H460 cells by 3074.0% or
2175.0%, respectively. When cells were exposed to the combina-
tion of both, their cell growth was inhibited by 4270.2% compared
to control cells (Po0.001) (Figure 7B, left panel). The enhanced
antiproliferative effect was also observed when NCI-H520 cells
were treated in combination with LY294002 (10mM) and docetaxel
(1nM) (Figure 7B, right panel). We further analysed drug
interaction employing median effect method. NCI-H460 cells
were cultured with variety concentrations of NVF (1–40mM)o r
docetaxel (0.001–10nM) either alone or in combination. Drug
interaction analysis indicated that growth inhibition was synergis-
tic (Figure 7C). The growth inhibition of NCI-H460 cells mediated
by combination of NFV and LY294002 was also synergistic (data
not shown).
NFV induces growth arrest and apoptosis of NCI-H460
xenografts in vivo
We evaluated the ability of NFV to inhibit the growth of NCI-H460
cells growing as xenografts in triple-deficient murine model.
Tumour volume was measured every week (Figure 8A), and
tumour weights were determined at autopsy (Figure 8B). NFV
markedly suppressed the growth and weights of NCI-H460
tumours. As shown in Figure 8A, the mean volume of NCI-H460
tumours in the mice who received NFV (7747465mm
3) was
significantly decreased compared with control mice
(219471041mm
3)( Po0.01). In addition, the difference of mean
tumour weights between these two groups (8497514mg NFV
treated, 180971047mg control diluent) was significant (Po0.01)
(Figure 8B). No mouse showed signs of wasting or other signs of
toxicity (data not shown).
In addition, we explored the ability of NFV to induce apoptosis
of NCI-H460 cells in vivo. After 3 weeks of therapy with or without
NFV, tumours were removed from nude mice and fixed. The
induction of apoptosis was assessed by TUNEL assay. Apoptosis
was induced in tumour cells from mice who received NFV.
Conversely, apoptotic cells were barely detectable in control
tumours (Figure 8C).
DISCUSSION
HIV-1 protease inhibitor NFV inhibited Akt kinase activity,
downregulated levels of Bcl-2, and induced growth arrest and
apoptosis of NSCLC cells in vitro and in vivo. Growth inhibition
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Figure 8 Effect of NFV in BALB/c triple-immunodeficient mice. (A)
Tumour volumes. NCI-H460 cells were injected bilaterally s.c. into BALB/c
nude mice, forming two tumours/mouse. Nelfinavir (60mgkg
 1mouse
 1)
was administered orally five times a week. Control mice received diluent
only. Tumours were measured every week. Each point represents the
mean7s.e. of 10 tumours. (B) Tumour weights at autopsy. After 3 weeks
of treatment, tumours were removed and weighed. Results represent
mean7s.e. of tumour weights. Statistical significance of the differences was
analysed by Mann–Whitney U-test. Bars, s.e.. (C) Terminal deoxyribo-
nucleotide transferase-mediated dUTP nick-end labelling assay. NCI-H460
xenographs were dissected from the mice at the end of the experiment,
fixed, and subjected to TUNEL assay to assess the proapoptotic effect of
NFV in vivo. Arrowheads indicate representative TUNEL-positive cells
(original  200). NFV, nelfinavir.
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smediated by NFV was p53-independent. Blockade of Akt signalling
in NSCLC cells by transfection of Akt siRNA caused down-
regulation of Bcl-2 and proliferation was slowed (Figure 5).
Phosphatidylinositol 3-kinase inhibitor LY294002 also decreased
proliferation of NSCLC cells. Conversely, forced-expression of Akt
in NSCLC cells partially reversed NFV-mediated growth inhibition
of these cells. These results suggest that NFV inhibited the growth
of NSCLC cells at least in part via inhibition of Akt signalling, with
Bcl-2 playing a central role. These observations are reminiscent of
studies done by other groups. Rapamycin, an inhibitor of mTOR
downstream of Akt, reversed the neoplastic phenotype of prostate
epithelial cells in transgenic mice expressing Akt (Majumder et al,
2004). When Bcl-2 was overexpressed in these mice, effect of
rapamycin was reduced (Majumder et al, 2004), suggesting that
Bcl-2 plays a pivotal role in apoptosis after the Akt/mTOR
signalling pathway has been blocked.
Akt contributes to drug resistance of cancer cells. Recently,
other investigators have shown that inhibition of Akt signalling
sensitised cancer cells to chemotherapy; rapamycin overcame
chemoresistance in murine lymphoma cells in vivo (Wendel et al,
2004). The PI3-K inhibitor LY294002 sensitised HL-60 human
myeloid leukemia cells to doxorubicin-induced apoptosis
(O’Gorman et al, 2000). In this study, we showed that NFV
enhanced the ability of docetaxel to inhibit the growth of NSCLC
cells (Figure 7B). Docetaxel has been used for individuals with
NSCLC as a first-line therapy in combination with cisplatin; the
effect of this combination therapy, however, is limited with a
1-year survival rate of less than 50% (Rigas, 2004). A clinical study
using docetaxel and an Akt inhibitor is warranted.
This study found that NFV downregulated levels of MMP-2 and
Bcl-2 in NSCLC cells (Figure 2). Recent studies showed that
expression of MMP-2 was regulated by Bcl-2 at transcriptional and
post-translational levels (choi et al, 2005). At the present time, it is
unclear whether NFV downregulated the level of MMP-2 via
inhibition of Bcl-2.
We previously showed that PIs induced growth arrest and
apoptosis of MM cells in association with blockade of the STAT 3
and ERK1/2 signal pathways (Ikezoe et al, 2004b). We, therefore,
investigated the effect of PIs on STAT 3 in NSCLC cells using an
ELISA-based assay. Neither NCI-H460 nor -H520 cells possessed
measurable STAT 3 DNA-binding activity; and AG490, an inhibitor
of the Janus family of tyrosine kinases (JAK), upstream of STAT 3,
was not able to affect their cell survival (data not shown). We also
explore the effect of PIs on ERK signalling in these cells by
Western blot analysis. Although NCI-H460 and -H520 cells
constitutively expressed p-ERK protein, NFV was not able to
downregulate levels of this cell survival factor in these cells
(Figure 3A), suggesting that growth inhibition mediated by PIs is
probably independent of inhibition of STAT 3 and ERK1/2
signalling in NSCLC cells.
Ritonavir and SAQ induced apoptosis of Kaposi sarcoma and
prostate cancer cells via inhibition of NF-kB activity (Pati et al,
2002; Ikezoe et al, 2004a). Nuclear factor-kB is active and plays an
important role in the development and progression of NSCLC
(Tabata et al, 2001; Mayo et al, 2003). As we previously described,
NCI-H460 and -H520 cells possess strong NF-kB DNA-binding
activity (Yang et al, 2004). Ritonavir inhibited NF-kB DNA-
binding activity in these cells by approximately 50% as measured
by an ELISA-based assay (figure not shown); however, NFV was
not able to block DNA-binding activity of this transcription factor
(data not shown). At present, the difference of biological function
between each PI remains unknown.
Insulin resistance has been identified in HIV-1-positive patients
treated with NFV (Grinspoon, 2001). Insulin activates the PI3-K/
Akt signalling, which stimulates glucose transport in adipose and
muscle cells (Grinspoon, 2001). Recent studies showed that NFV
blocked insulin-induced translocation of Akt to plasma membrane,
where PI3-K phosphorylates Akt, resulting in inactivation of Akt
(Ben-Romano et al, 2004). It could be the same as NFV inactivates
Akt in NSCLC cells.
Pharmacokinetic studies showed that Cmax was 6.667
2.33mgml
 1 (equals to 10mM) at 4.5h when NFV 1000mg was
given to healthy volunteers (n¼6, Japan Tobacco Specification,
Tokyo, Japan). This concentration of NFV was able to
inhibit growth of NCI-H460, -H520 and A549 cells in this study
(Figure 1).
In summary, Akt signalling may be a promising molecular target
for treatment of NSCLC. PIs might be useful as adjunctive
therapeutic agents for the treatment of individuals with NSCLC
and other types of cancer in which Akt signalling is active.
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